Janux Therapeutics Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Public

  • Employees
  • 114

Employees

  • Stock Symbol
  • JANX

Stock Symbol

  • Share Price
  • $10.08
  • (As of Friday Closing)

Janux Therapeutics General Information

Description

Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.

Contact Information

Website
www.januxrx.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 10955 Vista Sorrento Parkway
  • Suite 200
  • San Diego, CA 92130
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 10955 Vista Sorrento Parkway
  • Suite 200
  • San Diego, CA 92130
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Janux Therapeutics Stock Performance

As of 20-Nov-2026, Janux Therapeutics’s stock price is $10.08. Its current market cap is $617M with 61.2M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$10.08 $10.29 $10.05 - $35.34 $617M 61.2M 955K -$1.59

Janux Therapeutics Financials Summary

As of 30-Sep-2026, Janux Therapeutics has a trailing 12-month revenue of $23.3M.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 106,520 (136,293) 2,504,601 170,386
Revenue 23,289 10,000 10,588 8,083
EBITDA (137,704) (155,638) (96,787) (71,024)
Net Income (99,849) (113,625) (68,994) (58,293)
Total Assets 983,655 1,001,565 1,061,516 380,407
Total Debt 20,380 22,139 23,025 24,542
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Janux Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Janux Therapeutics‘s full profile, request access.

Request a free trial

Janux Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Janux Therapeutics‘s full profile, request access.

Request a free trial

Janux Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for canc
Drug Discovery
San Diego, CA
114 As of 2026

Philadelphia, PA
 

Emeryville, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Janux Therapeutics Competitors (41)

One of Janux Therapeutics’s 41 competitors is Carisma Therapeutics, a Formerly VC-backed company based in Philadelphia, PA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Carisma Therapeutics Formerly VC-backed Philadelphia, PA
Dynavax Technologies Formerly VC-backed Emeryville, CA
Adaptimmune Therapeutics Formerly VC-backed Abingdon, United Kingdom
CytomX Therapeutics Formerly VC-backed South San Francisco, CA
Cellectis Formerly VC-backed Paris, France
You’re viewing 5 of 41 competitors. Get the full list »

Janux Therapeutics Patents

Janux Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026236153-A1 Compositions and methods related to tumor activated antibodies Pending 06-May-2025
US-20260226170-A1 Multispecific polypeptides and methods of use thereof Pending 05-Feb-2025
WO-2026169835-A1 Multispecific polypeptides and methods of use thereof Pending 05-Feb-2025
US-20260234257-A1 T cell engagers and methods of use thereof Pending 05-Feb-2025
WO-2026169855-A1 T cell engagers and methods of use thereof Pending 05-Feb-2025 C12N5/0636
To view Janux Therapeutics’s complete patent history, request access »

Janux Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Janux Therapeutics ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

34.84 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,593

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Biotechnology

Subindustry

of 431

Rank

Percentile

To view Janux Therapeutics’s complete esg history, request access »

Janux Therapeutics FAQs

  • When was Janux Therapeutics founded?

    Janux Therapeutics was founded in 2017.

  • Where is Janux Therapeutics headquartered?

    Janux Therapeutics is headquartered in San Diego, CA.

  • What is the size of Janux Therapeutics?

    Janux Therapeutics has 114 total employees.

  • What industry is Janux Therapeutics in?

    Janux Therapeutics’s primary industry is Drug Discovery.

  • Is Janux Therapeutics a private or public company?

    Janux Therapeutics is a Public company.

  • What is Janux Therapeutics’s stock symbol?

    The ticker symbol for Janux Therapeutics is JANX.

  • What is the current stock price of Janux Therapeutics?

    As of 20-Nov-2026 the stock price of Janux Therapeutics is $10.08.

  • What is the current market cap of Janux Therapeutics?

    The current market capitalization of Janux Therapeutics is $617M.

  • What is Janux Therapeutics’s current revenue?

    The trailing twelve month revenue for Janux Therapeutics is $23.3M.

  • Who are Janux Therapeutics’s competitors?

    Carisma Therapeutics, Dynavax Technologies, Adaptimmune Therapeutics, CytomX Therapeutics, and Cellectis are some of the 41 competitors of Janux Therapeutics.

  • What is Janux Therapeutics’s annual earnings per share (EPS)?

    Janux Therapeutics’s EPS for 12 months was -$1.59.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process